Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech Inc. (traded on the NYSE American under the symbol AIM and, for a period, on the OTC Pink under AIMI/AIMID) is a healthcare company in the biotechnology industry that focuses on immuno-pharma research and development. According to the company, it is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. A central element of its work is its drug Ampligen, a first-in-class therapeutic double-stranded RNA (dsRNA) product that has been studied in a range of clinical settings.

Core focus and therapeutic areas

AIM ImmunoTech describes itself as an immuno-pharma company focused on developing therapeutics for cancers, immune disorders and viral diseases. Company disclosures and recent scientific presentations indicate that Ampligen has been studied for conditions such as solid tumors, viral diseases and disorders of the immune system. Clinical and preclinical data presented at scientific meetings discuss Ampligen’s activity in oncology, including its impact on the tumor microenvironment and its interaction with chemokines and immune cells.

The company reports that Ampligen has demonstrated broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. In oncology, data presented at the Annual Meeting of the American Association of Immunologists described systemic infusion of dsRNA (Rintatolimod, Ampligen) plus interferon and its effects on cytotoxic T lymphocyte (CTL) and regulatory T cell (Treg) trafficking into the tumor microenvironment, as well as selective activation of cancer tissues compared to healthy tissues.

Ampligen and intellectual property

AIM ImmunoTech’s overall intellectual property portfolio centers on Ampligen. The company reports that its patents cover the manufacture and use of Ampligen, including compositions and methods. A U.S. patent titled “Therapeutic Double Stranded RNA and Methods for Producing the Same” covers methods involving the manufacture of a range of therapeutic dsRNA products, including Ampligen, and provides patent protection for manufacturing until 2041. The company states that this manufacturing patent, combined with multiple compositions and methods patents involving Ampligen, secures its control over the synthesis and use of the drug.

According to AIM ImmunoTech, its patents include protection for Ampligen in the treatment of cancer, the post-COVID condition of fatigue and endometriosis, with specific patents issued in the United States and the Netherlands. The company also notes that its intellectual property protection for Ampligen includes multiple Orphan Drug Designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These orphan designations cover indications such as metastatic melanoma (US), renal cell carcinoma (US), pancreatic adenocarcinoma (US and EU), Ebola virus disease (US and EU), chronic fatigue syndrome/myalgic encephalomyelitis (US) and HIV (US).

Research collaborations and scientific presentations

AIM ImmunoTech’s disclosures highlight ongoing scientific engagement around Ampligen. The company reports that Pawel Kalinski, MD, PhD, a research oncologist who has served as a senior investigator for multiple oncology clinical studies involving Ampligen, has presented data on the drug at major scientific meetings. At the Annual Meeting of the American Association of Immunologists, Dr. Kalinski presented work on the selective effects of systemic infusion of dsRNA (Rintatolimod) plus interferon on chemokines in the tumor microenvironment and its combination with PD-1 blockade or chemotherapy.

In another presentation at the U.S.-Poland Science and Technology Symposium 2025, Dr. Kalinski discussed Ampligen as an example of how private-public partnerships can support the development of new oncology therapies. AIM ImmunoTech highlights this as evidence of how collaborations among companies, institutions and governmental agencies, including initiatives such as the Translational Research Cancer Centers Consortium and the Marie Skłodowska-Curie Symposia on Cancer Research and Care, may support joint clinical trials and development of new treatments.

Regulatory status and exchange listings

AIM ImmunoTech has reported several developments related to its stock exchange listings. The company announced that its common stock resumed trading on the NYSE American under the symbol AIM, and that NYSE Regulation staff withdrew a previous delisting determination and lifted a trading suspension after the company’s common stock traded above the threshold for low selling price issues as defined by Section 1003(f)(v) of the NYSE American Company Guide. During a period surrounding a 1-for-100 reverse stock split, the company’s common stock traded on the OTC Pink under the symbol AIMID, and it also disclosed trading on the Pink Open Market under the ticker AIMI.

The company has also received a warning notification from the NYSE American stating that it was not in compliance with minimum stockholders’ equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. AIM ImmunoTech reported that the NYSE American accepted a plan submitted by the company to regain compliance by June 11, 2026, and that the notice did not affect its business, operations or reporting requirements with the U.S. Securities and Exchange Commission.

Corporate governance and reporting

AIM ImmunoTech files reports with the U.S. Securities and Exchange Commission as a smaller reporting company under Item 10 of Regulation S-K. In its definitive proxy statement for the 2025 Annual Meeting of Stockholders, the company notes that it uses scaled disclosure obligations available to smaller reporting companies, which means it is not required to provide certain detailed executive compensation disclosures such as a Compensation Discussion and Analysis.

The company holds annual meetings of stockholders, where matters such as the election of directors, ratification of the independent registered public accounting firm, advisory votes on executive compensation and the frequency of such advisory votes are presented. Voting results from the 2025 Annual Meeting show that stockholders voted on the election of directors, ratification of BDO USA, P.C. as the independent registered public accounting firm, and advisory proposals regarding executive compensation and the frequency of compensation votes.

Financial reporting and SEC filings

AIM ImmunoTech files quarterly and annual reports, as well as current reports on Form 8-K, with the SEC. The company filed a Form 12b-25 notification of late filing for its Quarterly Report on Form 10-Q for the period ended September 30, 2025, stating that it was unable to file within the prescribed time due to delays in completing the required review and that additional time was needed to compile and verify data. The company indicated that it expected to file within the permitted extension period and noted anticipated changes in revenues and net loss compared to the prior-year periods.

In another Form 8-K, AIM ImmunoTech furnished a corporate presentation as a Regulation FD disclosure, noting that the information in the exhibit was furnished and not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934. The company also filed an 8-K referencing its Certificate of Incorporation as amended and restated, which was included as an exhibit and superseded prior individual exhibits containing portions of that document.

Business scale and company profile

Based on its disclosures, AIM ImmunoTech is a smaller reporting company focused on immuno-pharma research and development rather than large-scale commercial operations. The Form 12b-25 filing for the quarter ended September 30, 2025, references relatively modest revenue levels and ongoing net losses, which is consistent with a development-stage biotechnology company investing in research and clinical programs. The company’s focus on Ampligen, its associated intellectual property, and orphan drug designations reflects an emphasis on targeted therapeutic areas where regulatory incentives and specialized indications may be important.

Key considerations for investors and observers

According to AIM ImmunoTech’s own filings and press releases, key aspects of the company’s profile include:

• Therapeutic focus: Research and development of immuno-pharma therapeutics for cancers, immune disorders and viral diseases, including COVID-19.
• Lead asset: Ampligen, a first-in-class therapeutic dsRNA product studied in oncology and other indications, with clinical and preclinical data presented at scientific conferences.
• Intellectual property: Patents covering the manufacture and use of Ampligen, including a U.S. manufacturing patent extending to 2041 and additional patents for specific indications.
• Regulatory designations: Multiple Orphan Drug Designations from the FDA and EMA for diseases such as metastatic melanoma, renal cell carcinoma, pancreatic adenocarcinoma, Ebola virus disease, chronic fatigue syndrome/myalgic encephalomyelitis and HIV.
• Corporate status: A smaller reporting company under SEC rules, with stock trading on the NYSE American under AIM and prior trading on the OTC Pink under AIMI/AIMID during a reverse stock split and related listing process.
• Exchange compliance: A disclosed plan accepted by NYSE American to regain compliance with minimum stockholders’ equity requirements, with a specified timeframe.

All of these elements are drawn from AIM ImmunoTech’s own public statements, SEC filings and press releases, and they provide a framework for understanding the company’s business focus, development activities and regulatory context.